Herpes Zoster and Diabetes Mellitus: A Review

Diabetes Therapy

Volumn 9, Issue 2, 2018, Pages 545-550

  Papagianni, Marianthi ^a   Metallidis, Symeon ^a   Tziomalos, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Adjuvanted vaccine; Diabetes mellitus; Herpes zoster; Live attenuated vaccine; Post herpetic neuralgia; Vaccination

Indexed keywords

VARICELLA ZOSTER VACCINE;

CELL SURFACE; CELLULAR IMMUNITY; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; NONHUMAN; POSTHERPETIC NEURALGIA; REVIEW; RISK FACTOR; VACCINATION; VARICELLA ZOSTER VIRUS;

EID: 85044510448     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-018-0394-4     Document Type: Review

References (48)

1. Cohen JI. Clinical practice: herpes zoster. N Engl J Med. 2013;369:255–63.
2. Gnann JW Jr, Whitley RJ. Clinical practice herpes zoster. N Engl J Med. 2002;347:340–6.
3. Weller TH. Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med. 1983;309:1362–8.
4. Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med. 2014;371:1526–33.
5. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med. 2000;342:635–45.
6. Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42:325–34.
7. Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005–2009. J Infect. 2015;70:178–86.
8. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.
9. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41:281–8.
10. Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabet Med. 1997;14:29–34.
11. Plouffe JF, Silva J Jr, Fekety R, Allen JL. Cell-mediated immunity in diabetes mellitus. Infect Immun. 1978;21:425–9.
12. Pedicino D, Liuzzo G, Trotta F, et al. Adaptive immunity, inflammation, and cardiovascular complications in type 1 and type 2 diabetes mellitus. J Diabetes Res. 2013;2013:184258.
13. Weitzman D, Shavit O, Stein M, Cohen R, Chodick G, Shalev V. A population based study of the epidemiology of Herpes Zoster and its complications. J Infect. 2013;67:463–9.
14. Kawai K, Yawn BP. risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc. 2017;92:1806–21.
15. Gonzalez Chiappe S, Sarazin M, Turbelin C, et al. Herpes zoster: burden of disease in France. Vaccine. 2010;28:7933–8.
16. Dooling KL, Guo A, Patel M, et al. R. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67:103–8.
17. Yun H, Yang S, Chen L, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68:2328–37.
18. Ke CC, Lai HC, Lin CH, et al. Increased risk of herpes zoster in diabetic patients comorbid with coronary artery disease and microvascular disorders: a population-based study in Taiwan. PLoS ONE. 2016;11:e0146750.
19. Suaya JA, Chen SY, Li Q, Burstin SJ, Levin MJ. Incidence of herpes zoster and persistent post-zoster pain in adults with or without diabetes in the United States. Open Forum Infect Dis. 2014;1:ofu049.
20. Guignard AP, Greenberg M, Lu C, Rosillon D, Vannappagari V. Risk of herpes zoster among diabetics: a matched cohort study in a US insurance claim database before introduction of vaccination, 1997–2006. Infection. 2014;42:729–35.
21. Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39:537–44.
22. Heymann AD, Chodick G, Karpati T, et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection. 2008;36:226–30.
23. Nassaji-Zavareh M, Taheri R, Ghorbani R, Aminian M. Undiagnosed diabetes mellitus in patients with herpes zoster. Indian J Dermatol. 2008;53:119–21.
24. Chen HH, Lin IC, Chen HJ, Yeh SY, Kao CH. Association of herpes zoster and type 1 diabetes mellitus. PLoS ONE. 2016;11:e0155175.
25. Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014;348:g2911.
26. Okamoto S, Hata A, Sadaoka K, Yamanishi K, Mori Y. Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis. 2009;200:1606–10.
27. Muñoz-Quiles C, López-Lacort M, Ampudia-Blasco FJ, Díez-Domingo J. Risk and impact of herpes zoster on patients with diabetes: a population-based study, 2009–2014. Hum Vaccin Immunother. 2017;13:2606–11.
28. Chen HH, Lin CL, Yeh SY, Kao CH. Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in Asian patients with diabetes. QJM. 2016;109:91–5.
29. Aytac U, Dang NH. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4:11–8.
30. Zhao Y, Yang L, Wang X, Zhou Z. The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes. Diabetes Metab Res Rev. 2014;30:646–53.
31. Kim YN, Kim DW, Kim ED. Efficacy of continuous epidural block in acute herpes zoster: incidence and predictive factors of postherpetic neuralgia, a retrospective single-center study. Medicine (Baltimore). 2016;95:e4577.
32. Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study. Neurology. 2016;87:94–102.
33. Jih JS, Chen YJ, Lin MW, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000–2006. Acta Derm Venereol. 2009;89:612–6.
34. Torcel-Pagnon L, Bricout H, Bertrand I, et al. Impact of underlying conditions on zoster-related pain and on quality of life following zoster. J Gerontol A Biol Sci Med Sci. 2017;72:1091–7.
35. Bosco D, Plastino M, De Bartolo M, et al. Role of impaired glucose metabolism in the postherpetic neuralgia. Clin J Pain. 2013;29:733–6.
36. Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1–30 (quiz CE2-4).
37. Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Centers for Disease Control and Prevention (CDC). Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63:729–31.
38. Centers for Disease Control and Prevention (CDC). Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep. 2011;60:1528.
39. Oxman MN, Levin MJ, Johnson GR, et al. Shingles prevention study group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84.
40. Morrison VA, Johnson GR, Schmader KE, et al. Shingles prevention study group. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60:900–9.
41. Langan SM, Thomas SL, Smeeth L, Margolis DJ, Nitsch D. Zoster vaccination is associated with a reduction of zoster in elderly patients with chronic kidney disease. Nephrol Dial Transplant. 2016;31:2095–8.
42. Hata A, Inoue F, Yamasaki M, et al. Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus. J Infect. 2013;67:215–9.
43. Hata A, Inoue F, Hamamoto Y, Yamasaki M, et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabet Med. 2016;33:1094–101.
44. Lal H, Cunningham AL, Godeaux O, et al. ZOE-50 study group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–96.
45. Cunningham AL, Lal H, Kovac M, et al. ZOE-70 study group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–32.
46. Cohen JI. A new vaccine to prevent herpes zoster. N Engl J Med. 2015;372:2149–50.
47. Grupping K, Campora L, Douha M, et al. Immunogenicity and safety of the HZ/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine. J Infect Dis. 2017;216:1343–51.
48. Villaroel MA, Vahratian A. Vaccination coverage among adults with diagnosed diabetes: United States, 2015. NCHS Data Brief. 2016;265:1–8.